Proteins

7rh

Cat. No.: HY-U00444 CAS No.: 1429617-90-2 Molecular Formula: $C_{30}H_{29}F_3N_6O$

546.59 Molecular Weight:

Target: Discoidin Domain Receptor Pathway: Protein Tyrosine Kinase/RTK Storage:

-20°C Powder 3 years 4°C 2 years

In solvent -80°C 2 years

> -20°C 1 year

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 62.5 mg/mL (114.35 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.8295 mL	9.1476 mL	18.2952 mL
	5 mM	0.3659 mL	1.8295 mL	3.6590 mL
	10 mM	0.1830 mL	0.9148 mL	1.8295 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (3.81 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.81 mM); Clear solution

BIOLOGICAL ACTIVITY

Description 7rh (DDR1-IN-2) is a potent inhibitor of discoidin domain receptor 1 (DDR1), with an IC₅₀ of 13.1 nM, and also less potently inhibits DDR2, with an IC₅₀ of 203 nM. 7rh is a click chemistry reagent, it contains an Alkyne group and can undergo coppercatalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

IC50: 13.1 nM (DDR1), 203 nM (DDR2), 414 nM (Bcr-Abl), 2500 nM (c-Kit)[1] IC₅₀ & Target

> 7rh (compound 1) is a potent inhibitor of DDR1, with an IC₅₀ of 13.1 nM, and less potently inhibits DDR2, with an IC₅₀ of 203 nM. 7rh also shows inhibitory activities against Bcr-Abl and c-Kit, with IC₅₀s of 414 and 2500 nM, respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vitro

PROTOCOL

Kinase Assay [1]

The effects of compounds (including DDR1-IN-2) on the kinases DDR1 and DDR2 are assessed by using a LanthaScreen Eu kinase activity assay technology. Kinase reactions are performed in a 10 μ L solution in low-volume 384-well plates. The kinase reaction buffer consists of 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl₂, and 1 mM EGTA; the concentration of Fluorescein-Poly GAT substrate in the assay is 100 nM. Kinase reactions are initiated by the addition of 100 nM ATP in the presence of serially diluted compounds (DDR1-IN-2). The reactions are allowed to proceed for 1 h at room temperature before a 10 μ L preparation of EDTA (20 mM) and Eu-labeled antibody (4 nM) in TR-FRET dilution buffer are added. The final concentration of antibody in the assay well is 2 nM, and the final concentration of EDTA is 10 mM. The plate is allowed to incubate at room temperature for one more hour before the TR-FRET emission ratios of 665 nm/340 nm are acquired on a multilabel reader. Data analysis and curve fitting are performed using GraphPad Prism4 software^[1].

 $\label{eq:mce} \mbox{MCE has not independently confirmed the accuracy of these methods. They are for reference only.}$

CUSTOMER VALIDATION

- Cell Death Differ. 2023 Apr 28.
- Oncogene. 2022 Feb 9.
- · Research Square Print. 2022 Jun.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Wang Z, et al. Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. ACS Med Chem Lett. 2017 Feb 9:8(3):327-332.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA